Article Link: FDA Approves Barhemsys (amisulpride) for the Treatment and Prevention of PONV Cambridge, UK and Indianapolis, US – 27 Febru...
FDA Approves Nexlizet (bempedoic acid and ezetimibe) to Lower LDL-Cholesterol
Article Link: FDA Approves Nexlizet (bempedoic acid and ezetimibe) to Lower LDL-Cholesterol ANN ARBOR, Mich., Feb. 26, 2020 (GLOBE NEWSWI...
Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
Article Link: Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breas...
FDA Approves Vyepti (eptinezumab-jjmr) Intravenous Injection for the Preventive Treatment of Migraine
Article Link: FDA Approves Vyepti (eptinezumab-jjmr) Intravenous Injection for the Preventive Treatment of Migraine Valby, Denmark, Febru...
FDA Approves Nexletol (bempedoic acid) to Lower LDL-Cholesterol
Article Link: FDA Approves Nexletol (bempedoic acid) to Lower LDL-Cholesterol ANN ARBOR, Mich., Feb. 21, 2020 (GLOBE NEWSWIRE) — Es...
FDA Approves Anjeso (meloxicam injection) for the Management of Moderate to Severe Pain
Article Link: FDA Approves Anjeso (meloxicam injection) for the Management of Moderate to Severe Pain MALVERN, Pa., Feb. 20, 2020 (GLOBE ...
Horizon Therapeutics plc Announces U.S. FDA Approval of New Dosage Form for Procysbi (Cysteamine Bitartrate) Delayed-Release Oral Granules
Article Link: Horizon Therapeutics plc Announces U.S. FDA Approval of New Dosage Form for Procysbi (Cysteamine Bitartrate) Delayed-Release Oral Granul...
Potential New Tech in Treatment of Disease
Good day everyone, As you know we cover many biotech stocks. We’ve talked about companies developing pharma products with big potential. We’ve talked ...
FDA Approves GSK’s Voltaren Arthritis Pain for Over-the-Counter Use in the United States
Article Link: FDA Approves GSK’s Voltaren Arthritis Pain for Over-the-Counter Use in the United States Warren, New Jersey, USA — F...
Traders News Source Remains One of The Most Sought After Small Cap Stock Newsletters. Over 1000% in Bookable Gains This Year so Far
Traders News Source Remains One of The Most Sought After Small Cap Stock Newsletters Over 1000% in Bookable Gains This Year so Far Updates and what to...